Improved glycemic control with the MiniMed 780G system in latent autoimmune diabetes and type 1 diabetes: a real-world observational study
Authors' conclusion
MiniMed™ 780G markedly improves glycemic control in people with LADA, supporting AHCLS as an effective therapeutic strategy in this population.
Study context
- Population
- Insulin-treated adults with latent autoimmune diabetes in adults (LADA), BMI-matched with LADA on multiple daily injections (MDI) + continuous glucose monitoring (CGM) and people with T1D on Automated Hybrid Closed Loop System (AHCLS) or MDI + CGMBMI-matched
- Exposure
- MiniMed 780G AHCLS vs MDI + CGM, in LADA and T1D
- Outcome
- Time in range (TIR) (CGM metrics)
Methodological detailsreal-world, BMI-matched, multivariable regression adjusted for age, sex and diabetes duration, interaction analysis
- Real-world
- BMI-matched
- Multivariable regression adjusted for age, sex and diabetes duration
- Interaction analysis
Main finding
As reported in the abstract
TIR
AHCLS vs MDI: P < 0.001 · LADA vs T1D: P for interaction = 0.53
Observational data: associations, not effects.
Further findings
Patients meeting all CGM targets — AHCLS vs MDI
P < 0.001
| Outcome | P value |
|---|---|
| Patients meeting all CGM targetsLADA vs T1D | P for interaction = 0.39 |
Original publication
Improved glycemic control with the MiniMed 780G system in latent autoimmune diabetes and type 1 diabetes: a real-world observational study. Diabetes Res Clin Pract. Published 6 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →